AOA DxBlood Test for Early Detection of Ovarian Cancer

AOA DX – Early Cancer Detection

The Future of Early Cancer Detection is Now

Key Features

• GlycoLocate™: Revolutionary tumor marker ganglioside platform for life-saving early cancer detection.
• AKRIVIS GD™: Novel blood test utilizing tumor marker gangliosides to detect early-stage ovarian cancer.
• AI Integration: Advanced data science techniques for remarkable insights into early cancer detection.

Use Cases

• Women's Health: Focused on early detection of cancers affecting women, particularly ovarian cancer.
• Medical Providers: Tools for healthcare providers to offer early and accurate cancer detection.
• Research and Development: Innovative platform for ongoing cancer research and biomarker discovery.

Pricing

AOA Dx offers cost-effective solutions designed to bring advanced medical technologies from research to practical use. Contact us for detailed pricing information tailored to your needs.

Teams

AOA Dx is a team of industry experts and entrepreneurs dedicated to innovation in women’s health. We are committed to developing impactful and affordable medical technologies. Join us in transforming women's health through early cancer detection. Explore career opportunities with us.